KLDO News and Press, Kaleido Biosciences Inc. From 11/02/20

- Topline Data for KB109 for the Treatment of Mild-to-Moderate COVID-19 Expected in the First Quarter of 202 1 - LEXINGTON, Mass., Nov. 02, 2020 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO) today announced financial results for the third quart...

Gainers: Kaixin Auto (KXIN) +317%.Dragon Victory International (LYL) +107%.Marine Petroleum Trust (MARPS) +62%.BOQI International Medical (BIMI) +59%.Dogness (DOGZ) +45%.Dunxin Financial (DXF) +44%.BioSpecifics Technologies (BSTC) +44%.Front Yard Residential (RESI) +35%.Li...

Ex vivo data from candidate KB109, under evaluation in two clinical studies for COVID-19, to be presented at IDWeek 2020 Data from studies of KB39 and KB174 to be presented at The Liver Meeting ® 2020 , the AASLD Annual Meeting ...

Citing updated enrollment projections, Kaleido Biosciences (KLDO) now expects to report topline data from its K031 study evaluating KB109 in patients with mild-to-moderate COVID-19 in Q1 2021 instead of this quarter.Results from another study, KB032, testing KB109 in the same patient populati...

LEXINGTON, Mass., Oct. 06, 2020 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), today announced an update to its ongoing COVID-19 clinical development program evaluating KB109 when added to supportive self-care (SSC) in outpatients with mild-to-moderate COVID-19 disease. Updat...

Kaleido Biosciences (KLDO) +3% appoints President and CEO, effective October 13, 2020.Mr. Menichella succeeds Alison Lawton, who stepped down to attend to a family health matter but continued to work with the Company in the Office of the CEO alongside Executive Chair Mike Bonney. Mr...

LEXINGTON, Mass., Oct. 01, 2020 (GLOBE NEWSWIRE) -- Kaleido Biosciences, Inc. (Nasdaq: KLDO), a clinical-stage healthcare company with a chemistry-driven approach to targeting the microbiome to treat disease and improve human health, announced that Daniel Menichella has been appointed Presi...

Kaleido's stock has been on a tear in the past week - gaining >100% on news of a new trial initiation in ulcerative colitis. The microbiome metabolic therapy specialist has 4 candidates in development, one of which targets treatment of COVID-19 in non-hospitalised patients - a larg...

Gainers: CTI BioPharma (CTIC) +99%, Genetron Holdings (GTH) +26%, Allena Pharmaceuticals (ALNA) +23%, Neurotrope (NTRP) +20%, Kaleido Biosciences (KLDO) +11%.Losers: Aptorum Group (APM) -41%, Adial Pharmaceuticals (ADIL) -21%, Avalon...

Kaleido Biosciences (KLDO) -1.2% in premarket has dosed the first patient in a clinical study evaluating KB295, a Microbiome Metabolic Therapy candidate, for the treatment of ulcerative colitis ((UC)), an inflammatory bowel disease characterized by long-lasting i...